Lucas Moreno

2.8k total citations
93 papers, 1.4k citations indexed

About

Lucas Moreno is a scholar working on Neurology, Molecular Biology and Genetics. According to data from OpenAlex, Lucas Moreno has authored 93 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Neurology, 31 papers in Molecular Biology and 24 papers in Genetics. Recurrent topics in Lucas Moreno's work include Neuroblastoma Research and Treatments (52 papers), Glioma Diagnosis and Treatment (24 papers) and Cancer, Hypoxia, and Metabolism (18 papers). Lucas Moreno is often cited by papers focused on Neuroblastoma Research and Treatments (52 papers), Glioma Diagnosis and Treatment (24 papers) and Cancer, Hypoxia, and Metabolism (18 papers). Lucas Moreno collaborates with scholars based in Spain, United Kingdom and France. Lucas Moreno's co-authors include Stergios Zacharoulis, Andrew D.J. Pearson, Francisco Bautista, S. Ashley, Lynley V. Marshall, Gilles Vassal, Catriona Duncan, Dominique Valteau‐Couanet, Fernando Carceller and Birgit Geoerger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Lucas Moreno

88 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucas Moreno Spain	22	642	521	340	281	280	93	1.4k
Lynley V. Marshall United Kingdom	17	309 0.5×	459 0.9×	292 0.9×	439 1.6×	207 0.7×	62	1.2k
Suzanne Shusterman United States	23	738 1.1×	645 1.2×	157 0.5×	642 2.3×	384 1.4×	63	1.7k
Stephen S. Roberts United States	20	743 1.2×	508 1.0×	126 0.4×	382 1.4×	303 1.1×	73	1.3k
Harriet Druker Canada	17	296 0.5×	553 1.1×	136 0.4×	478 1.7×	338 1.2×	23	1.6k
Anita Villani Canada	14	243 0.4×	392 0.8×	132 0.4×	353 1.3×	253 0.9×	46	1.2k
Jean Claude Gentet France	24	522 0.8×	418 0.8×	569 1.7×	301 1.1×	115 0.4×	46	1.4k
Richard Kadota United States	22	525 0.8×	361 0.7×	698 2.1×	317 1.1×	103 0.4×	46	1.6k
Kenneth B. DeSantes United States	16	374 0.6×	275 0.5×	108 0.3×	354 1.3×	175 0.6×	32	1.1k
L. S. Lashford United Kingdom	23	622 1.0×	687 1.3×	950 2.8×	277 1.0×	235 0.8×	47	1.9k
Amanda F. Cashen United States	29	443 0.7×	629 1.2×	549 1.6×	1.0k 3.7×	118 0.4×	121	2.9k

Countries citing papers authored by Lucas Moreno

Since Specialization

Citations

This map shows the geographic impact of Lucas Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucas Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucas Moreno more than expected).

Fields of papers citing papers by Lucas Moreno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucas Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucas Moreno. The network helps show where Lucas Moreno may publish in the future.

Co-authorship network of co-authors of Lucas Moreno

This figure shows the co-authorship network connecting the top 25 collaborators of Lucas Moreno. A scholar is included among the top collaborators of Lucas Moreno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucas Moreno. Lucas Moreno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moreno, Lucas, Steven G. DuBois, Nick Bird, et al.. (2025). A 2035 Clinical Research Vision and Roadmap for High‐Risk Neuroblastoma. Pediatric Blood & Cancer. 72(6). e31660–e31660. 1 indexed citations

Moreno, Lucas, Ricardo López Almaraz, Julia Balaguer, et al.. (2025). Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease. Clinical & Translational Oncology. 27(8). 3421–3431. 1 indexed citations

Moreno, Lucas, Pierre Teira, James M. Croop, et al.. (2023). A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. Frontiers in Pediatrics. 11. 1183295–1183295. 5 indexed citations

Jiménez, Carlos, Lucas Moreno, & Miguel F. Segura. (2023). Epigenetic therapies for neuroblastoma: immunogenicity awakens. Molecular Oncology. 17(5). 718–721. 3 indexed citations

Hladun, Raquel, Gabriela Guillén, Gabriel Gallo-Oller, et al.. (2023). Targeting the Hedgehog Pathway in Rhabdomyosarcoma. Cancers. 15(3). 727–727. 4 indexed citations

Pons, Guillem, Gabriel Gallo-Oller, Miguel F. Segura, et al.. (2023). Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon. Cancers. 15(6). 1636–1636. 1 indexed citations

Doz, François, Nicolás André, Jaume Mora, et al.. (2023). Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study.. Journal of Clinical Oncology. 41(16_suppl). 10040–10040. 3 indexed citations

Schoot, Reineke A., Natasha K. A. van Eijkelenburg, Alwin D. R. Huitema, et al.. (2023). A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.. Journal of Clinical Oncology. 41(16_suppl). 10036–10036. 1 indexed citations

Jiménez, Carlos, Mariona Nadal‐Ribelles, Laura Devis, et al.. (2022). Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program. Molecular Cancer. 21(1). 175–175. 7 indexed citations

10.

Gallo-Oller, Gabriel, Guillem Pons, Miguel F. Segura, et al.. (2021). Dickkopf Proteins and Their Role in Cancer: A Family of Wnt Antagonists with a Dual Role. Pharmaceuticals. 14(8). 810–810. 12 indexed citations

11.

Gallo-Oller, Gabriel, Guillem Pons, Miguel F. Segura, et al.. (2021). Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo. International Journal of Molecular Sciences. 22(23). 12921–12921. 6 indexed citations

12.

Poon, Evon, Matthew Clarke, Neil P. Jerome, et al.. (2020). Noninvasive MRI Native T1 Mapping Detects Response to MYCN -targeted Therapies in the Th- MYCN Model of Neuroblastoma. Cancer Research. 80(16). 3424–3435. 21 indexed citations

13.

Amoroso, Loredana, Victoria Castel, Gianni Bisogno, et al.. (2020). Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer. 135. 89–97. 15 indexed citations

14.

Rojas, Teresa de, María C. Puertas, Francisco Bautista, et al.. (2019). Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. Clinical & Translational Oncology. 21(12). 1687–1698. 3 indexed citations

15.

Rojas, Teresa de, E. Clementel, J. Giralt, et al.. (2019). Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. European Journal of Cancer. 114. 36–46. 8 indexed citations

16.

Smith, Jennifer R., Lucas Moreno, Simon P. Heaton, et al.. (2015). Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology. 10(4). 538–552. 16 indexed citations

17.

Moreno, Lucas, Lynley V. Marshall, Andrew D.J. Pearson, et al.. (2014). A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. Clinical Cancer Research. 21(2). 267–273. 39 indexed citations

18.

Barone, Giuseppe, Deborah A. Tweddle, Jason M. Shohet, et al.. (2014). MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets. 15(1). 114–123. 33 indexed citations

19.

Kieran, Mark W., Darren Hargrave, Stewart Goldman, et al.. (2013). A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL SONIDEGIB (LDE225) VERSUS TEMOZOLOMIDE IN PATIENTS WITH HEDGEHOG PATHWAY-ACTIVATED RELAPSED MEDULLOBLASTOMA. UCL Discovery (University College London). 5 indexed citations

20.

Moreno, Lucas, et al.. (2012). Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. Journal of Neuro-Oncology. 111(2). 169–176. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact